Logan Graham, the leader of the red team, recalled the bioweapons scare as an example of the challenges Anthropic faces at a pivotal moment for the company and the world. Anthropic is the frontier AI ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...

Artificial intelligence is rapidly inventing new drugs for diseases from Parkinson's disease and antibiotic-resistant superbugs to rare lung conditions.

Your first 3D prints should be simple, practical, and satisfying to finish. This list highlights projects that print easily ...

AI infrastructure can't evolve as fast as model innovation. Memory architecture is one of the few levers capable of accelerating deployment cycles. Enter SOCAMM2 ...

This edition of Market Factors starts with an extremely bullish strategist from HSBC who believes most of the bad market news is behind us. We move on to takeaways from a recent technology lovefest in ...

By Joseph Tulloch For years, AI safety experts have been warning of a future moment where AI models become advanced enough to ...

The unbridled hype of the mid-2020s is finally colliding with the structural and infrastructure limits of 2026.